Perceive Bio concludes Phase IIa trial enrolment for GA
Perceive Bio concludes Phase IIa trial enrolment for GA
Perceive Bio has concluded enrolment ahead of targets in its Phase IIa JOURNEY clinical study evaluating VOY-101, an experimental gene therapy for GA caused by dry AMD.